Bioventus selects Pfizer as exclusive distribution partner for hip, knee OA solution in Brazil: 3 notes

Biologics

Bioventus received approval to market Durolane for hip and knee osteoarthritis in Brazil and selected Pfizer as its exclusive distribution partner.

Here are three things to know:

1. The Agência Nacional de Vigilância Sanitária granted Bioventus approval to market the single-injection joint-fluid treatment for mild to moderate hip and knee osteoarthritis.

2. Pfizer has more than 100 sales representatives throughout Brazil. The company will offer Durolane as part of its arthritis pain management portfolio.

3. According to Bioventus' CEO Tony Bihl, Brazil is the largest Latin American market for osteoarthritis pain solutions.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers